JP7591155B2 - 置換ピリドトリアジン化合物及びその使用 - Google Patents

置換ピリドトリアジン化合物及びその使用 Download PDF

Info

Publication number
JP7591155B2
JP7591155B2 JP2023543136A JP2023543136A JP7591155B2 JP 7591155 B2 JP7591155 B2 JP 7591155B2 JP 2023543136 A JP2023543136 A JP 2023543136A JP 2023543136 A JP2023543136 A JP 2023543136A JP 7591155 B2 JP7591155 B2 JP 7591155B2
Authority
JP
Japan
Prior art keywords
pharma
acceptable salt
compound
ceutically acceptable
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023543136A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024503116A (ja
Inventor
ハン チュー，
ブエンロストロ， アナ ゼット． ゴンザレス
ホンヤン グオ，
シャオチュン ハン，
アンナ イー． ハートレー，
ラン ジアン，
ジャヤオ リー，
デイビッド ダブリュー． リン，
マイケル エル． ミッチェル，
デヴァン ナドゥサンビ，
グレッグ エム． シュワルツワルダー，
スザンヌ エム． シェフチェク，
バーゲン， マシュー ジェイ． フォン
チャオイン ウー，
ホン ヤン，
ジェニファー アール． ジャン，
Original Assignee
ギリアード サイエンシーズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ギリアード サイエンシーズ， インコーポレイテッド filed Critical ギリアード サイエンシーズ， インコーポレイテッド
Publication of JP2024503116A publication Critical patent/JP2024503116A/ja
Priority to JP2024165518A priority Critical patent/JP7759459B2/ja
Application granted granted Critical
Publication of JP7591155B2 publication Critical patent/JP7591155B2/ja
Priority to JP2025030163A priority patent/JP2025087755A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • AIDS & HIV (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2023543136A 2021-01-19 2022-01-18 置換ピリドトリアジン化合物及びその使用 Active JP7591155B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024165518A JP7759459B2 (ja) 2021-01-19 2024-09-24 置換ピリドトリアジン化合物及びその使用
JP2025030163A JP2025087755A (ja) 2021-01-19 2025-02-27 置換ピリドトリアジン化合物及びその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163139237P 2021-01-19 2021-01-19
US63/139,237 2021-01-19
US202163190461P 2021-05-19 2021-05-19
US63/190,461 2021-05-19
PCT/US2022/012773 WO2022159387A1 (en) 2021-01-19 2022-01-18 Substituted pyridotriazine compounds and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024165518A Division JP7759459B2 (ja) 2021-01-19 2024-09-24 置換ピリドトリアジン化合物及びその使用

Publications (2)

Publication Number Publication Date
JP2024503116A JP2024503116A (ja) 2024-01-24
JP7591155B2 true JP7591155B2 (ja) 2024-11-27

Family

ID=80514578

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2023543136A Active JP7591155B2 (ja) 2021-01-19 2022-01-18 置換ピリドトリアジン化合物及びその使用
JP2024165518A Active JP7759459B2 (ja) 2021-01-19 2024-09-24 置換ピリドトリアジン化合物及びその使用
JP2025030163A Pending JP2025087755A (ja) 2021-01-19 2025-02-27 置換ピリドトリアジン化合物及びその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024165518A Active JP7759459B2 (ja) 2021-01-19 2024-09-24 置換ピリドトリアジン化合物及びその使用
JP2025030163A Pending JP2025087755A (ja) 2021-01-19 2025-02-27 置換ピリドトリアジン化合物及びその使用

Country Status (26)

Country Link
US (4) US11613546B2 (https=)
EP (2) EP4196479B9 (https=)
JP (3) JP7591155B2 (https=)
KR (1) KR20230134529A (https=)
AU (2) AU2022210247C1 (https=)
CA (1) CA3202957A1 (https=)
CL (2) CL2023002074A1 (https=)
CO (1) CO2023009518A2 (https=)
CR (1) CR20230315A (https=)
DK (1) DK4196479T5 (https=)
DO (1) DOP2023000139A (https=)
ES (1) ES2968058T3 (https=)
FI (1) FI4196479T3 (https=)
HR (1) HRP20231654T2 (https=)
HU (1) HUE064467T2 (https=)
IL (1) IL304222A (https=)
LT (1) LT4196479T (https=)
MX (1) MX2023008137A (https=)
PE (2) PE20231297A1 (https=)
PL (1) PL4196479T3 (https=)
PT (1) PT4196479T (https=)
SA (1) SA523441639B1 (https=)
SI (1) SI4196479T1 (https=)
TW (2) TW202408533A (https=)
WO (1) WO2022159387A1 (https=)
ZA (1) ZA202306360B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024173998A (ja) * 2021-01-19 2024-12-13 ギリアード サイエンシーズ， インコーポレイテッド 置換ピリドトリアジン化合物及びその使用

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020197991A1 (en) 2019-03-22 2020-10-01 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
IL295677B1 (en) 2020-02-24 2026-04-01 Gilead Sciences Inc Tetracyclic compounds for the treatment of HIV infection
CA3192145A1 (en) 2020-09-30 2022-04-07 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
EP4384178A4 (en) * 2021-08-11 2025-07-02 Merck Sharp & Dohme Llc POLYCYCLIC CAP-DEPENDENT ENDONUCLEASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF INFLUENZA
TWI856796B (zh) 2022-04-06 2024-09-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
US20250296932A1 (en) 2024-03-01 2025-09-25 Gilead Sciences, Inc. Pharmaceutical compositions comprising hiv integrase inhibitors
WO2025184452A1 (en) 2024-03-01 2025-09-04 Gilead Sciences, Inc. Solid forms of hiv integrase inhibitors
US20250296933A1 (en) 2024-03-01 2025-09-25 Gilead Sciences, Inc. Methods and intermediates for preparing therapeutic compounds
WO2026020086A1 (en) 2024-07-19 2026-01-22 Gilead Sciences, Inc. Methods and pharmaceutical formulations for treating viral infections

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019160783A1 (en) 2018-02-15 2019-08-22 Merck Sharp & Dohme Corp. Tricyclic heterocycle compounds useful as hiv integrase inhibitors
WO2019230858A1 (ja) 2018-05-31 2019-12-05 塩野義製薬株式会社 多環性カルバモイルピリドン誘導体
WO2019236396A1 (en) 2018-06-05 2019-12-12 Merck Sharp & Dohme Corp. Tricyclic heterocycle compounds useful as hiv integrase inhibitors
WO2020075080A1 (en) 2018-10-10 2020-04-16 Janssen Biopharma, Inc. Macrocyclic flu endonuclease inhibitors
WO2020197991A1 (en) 2019-03-22 2020-10-01 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
WO2021007506A1 (en) 2019-07-11 2021-01-14 Nanjing Zhengxiang Pharmaceuticals Co., Ltd. Compounds useful to treat influenza virus infections

Family Cites Families (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
EP2359833A1 (en) 2003-04-25 2011-08-24 Gilead Sciences, Inc. Antiviral phosphonate analogs
ME03423B (me) 2004-07-27 2020-01-20 Gilead Sciences Inc Fosfonatni analozi jedinjenja hiv inhibitora
ATE516026T1 (de) 2005-02-21 2011-07-15 Shionogi & Co Bicyclisches carbamoylpyridonderivat mit hiv- integrase-hemmender wirkung
CN101146811B (zh) 2005-03-31 2012-01-11 P.安杰莱蒂分子生物学研究所 Hiv整合酶抑制剂
US8129385B2 (en) 2005-04-28 2012-03-06 Shionogi & Co., Ltd. Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness
JP2006342115A (ja) 2005-06-10 2006-12-21 Shionogi & Co Ltd Ｈｉｖインテグラーゼ阻害活性を有する多環性化合物
US20080214527A1 (en) 2005-08-04 2008-09-04 Takashi Kawasuji Hiv Integrase Inhibitors
JP2009513640A (ja) 2005-10-27 2009-04-02 メルク エンド カムパニー インコーポレーテッド Ｈｉｖインテグラーゼインヒビター
EA200801144A1 (ru) 2005-10-27 2008-10-30 Сионоги Энд Ко., Лтд. Полициклическое карбамоилпиридоновое производное, обладающее ингибиторной активностью в отношении интегразы вич
TW200811153A (en) 2006-06-23 2008-03-01 Japan Tobacco Inc 6-(heterocyclyl-substituted benzyl)-4-oxoquinoline compound and use thereof as HIV integrase inhibitor
US20100056516A1 (en) 2006-07-17 2010-03-04 Williams Peter D 1-hydroxy naphthyridine compounds as anti-hiv agents
WO2008048538A1 (en) 2006-10-18 2008-04-24 Merck & Co., Inc. Hiv integrase inhibitors
MX2010005334A (es) 2007-11-16 2010-05-27 Boehringer Ingelheim Int Inhibidores de la replicacion del virus de la inmunodeficiencia humana.
CN101918372B (zh) 2008-01-08 2014-03-26 默沙东公司 用于制备n-取代的羟基嘧啶酮羧酰胺类化合物的方法
US8129398B2 (en) 2008-03-19 2012-03-06 Bristol-Myers Squibb Company HIV integrase inhibitors
TWI443098B (zh) 2008-03-24 2014-07-01 Medivation Technologies Inc 吡啶并〔３，４－ｂ〕吲哚及使用方法
WO2009154870A1 (en) 2008-05-05 2009-12-23 Merck & Co., Inc. Hiv integrase inhibitors
JP5539978B2 (ja) 2008-07-02 2014-07-02 アベキサ・リミテッド チアゾピリミジノンおよびその使用
EP2330902B1 (en) 2008-07-25 2012-11-14 GlaxoSmithKline LLC Chemical compounds
EP2320909B8 (en) 2008-07-25 2016-03-30 VIIV Healthcare Company Chemical compounds
WO2010011819A1 (en) 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
WO2010011818A1 (en) 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
WO2010011815A1 (en) 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
SI2320908T1 (sl) 2008-07-25 2014-05-30 Viiv Healthcare Company Predzdravila dolutegravirja
WO2010042392A2 (en) 2008-10-06 2010-04-15 Merck & Co., Inc. Hiv integrase inhibitors
ES2467108T3 (es) 2008-12-09 2014-06-11 Gilead Sciences, Inc. Moduladores de receptores tipo toll
CA2744019C (en) 2008-12-11 2017-03-14 Shionogi & Co., Ltd. Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates
EP2391212A4 (en) 2009-01-28 2012-08-08 BROKEN COMPOUNDS AS HIV INTEGRASE INHIBITORS
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
LT2444400T (lt) 2009-06-15 2018-06-11 Shionogi & Co., Ltd. Pakeistasis policiklinis karbamoilpiridono darinys
WO2011011483A1 (en) 2009-07-22 2011-01-27 Glaxosmithkline Llc Chemical compounds
WO2011025683A1 (en) 2009-08-26 2011-03-03 Merck Sharp & Dohme Corp. Hiv integrase inhibitors
WO2011045330A1 (en) 2009-10-13 2011-04-21 Tibotec Pharmaceuticals Macrocyclic integrase inhibitors
PE20121524A1 (es) 2010-01-27 2012-12-03 Viiv Healthcare Co Combinaciones de compuestos que comprenden inhibidores de la integrasa de vih y otros agentes terapeuticos
PE20130010A1 (es) 2010-02-26 2013-02-05 Japan Tobacco Inc Derivado de 1,3,4,8-tetrahidro-2h-pirido[1,2-a]pirazina como inhibidor de la integrasa del vih
RU2567385C2 (ru) 2010-04-02 2015-11-10 ЯНССЕН Ар ЭНД Ди АЙРЛЭНД Макроциклические ингибиторы интегразы
WO2011129095A1 (ja) 2010-04-12 2011-10-20 塩野義製薬株式会社 インテグラーゼ阻害活性を有するピリドン誘導体
WO2011139637A1 (en) 2010-05-03 2011-11-10 Philadelphia Health & Education Corporation Small-molecule modulators of hiv-1 capsid stability and methods thereof
KR20130124291A (ko) 2010-07-02 2013-11-13 길리애드 사이언시즈, 인코포레이티드 Ｈｉｖ 항바이러스 화합물로서의 2-퀴놀리닐-아세트산 유도체
AP2013006706A0 (en) 2010-07-02 2013-02-28 Gilead Sciences Inc Napht-2-ylacetic acid derivatives to treat AIDS
US20140011995A1 (en) 2010-08-05 2014-01-09 Yukihito Sumino Process for Preparing Compound Having HIV Integrase Inhibitory Activity
TWI577377B (zh) 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
EP2632454A1 (en) 2010-10-29 2013-09-04 Merck Sharp & Dohme Corp. Hiv integrase inhibitors
US8835411B2 (en) 2010-12-10 2014-09-16 Bristol-Myers Squibb Company HIV integrase inhibitors
BR112013027096A2 (pt) 2011-04-21 2016-12-27 Gilead Sciences Inc compostos de benzotiazol e seu uso farmacêutico
EP2729448B1 (en) 2011-07-06 2015-09-09 Gilead Sciences, Inc. Compounds for the treatment of hiv
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
EP2774928B1 (en) 2011-10-12 2017-08-30 Shionogi & Co., Ltd. Polycyclic pyridone derivative having integrase-inhibiting activity
US9399645B2 (en) 2011-12-20 2016-07-26 Boehringer Ingelheim International Gmbh Inhibitors of HIV replication
ES2571479T3 (es) 2012-04-20 2016-05-25 Gilead Sciences Inc Derivados del ácido benzotiazol-6-il acético y su uso para tratar una infección por VIH
WO2014004279A1 (en) 2012-06-25 2014-01-03 Sunpower Corporation Brace for solar module array
WO2014008636A1 (en) 2012-07-11 2014-01-16 Merck Sharp & Dohme Corp. Macrocyclic compounds as hiv integrase inhibitors
US20150166520A1 (en) 2012-07-20 2015-06-18 Merck Sharp & Dohme Corp. Amido-substituted pyrimidinone derivatives useful for the treatment of hiv infection
US8906929B2 (en) 2012-08-16 2014-12-09 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
DE102012220513B4 (de) 2012-11-12 2023-02-16 Bayerische Motoren Werke Aktiengesellschaft Verfahren und Vorrichtung zur Herstellung eines Druckgussteils
EP2931730B1 (en) 2012-12-17 2019-08-07 Merck Sharp & Dohme Corp. 4-pyridinonetriazine derivatives as hiv integrase inhibitors
EA030003B1 (ru) 2012-12-21 2018-06-29 Джилид Сайэнс, Инк. Полициклическое карбамоилпиридоновое соединение и его фармацевтическое применение для лечения вич-инфекции
US20140221378A1 (en) 2012-12-27 2014-08-07 Japan Tobacco Inc. SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND PHARMACEUTICAL USE OF SAME AS HIV INTEGRASE INHIBITOR
EP2986291B1 (en) 2013-04-16 2020-05-27 Merck Sharp & Dohme Corp. 4-pyridone derivative compounds and uses thereof as hiv integrase inhibitors
AU2014267951A1 (en) 2013-05-17 2015-11-19 Merck Sharp & Dohme Corp. Fused Tricyclic Heterocyclic compounds as HIV integrase inhibitors
US9951079B2 (en) 2013-06-13 2018-04-24 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as HIV integrase inhibitors
NO2865735T3 (https=) 2013-07-12 2018-07-21
SI3019503T1 (sl) 2013-07-12 2017-11-30 Gilead Sciences, Inc. Policiklične karbamoilpiridonske spojine in njihova uporaba za zdravljenje HIV infekcij
WO2015039348A1 (en) 2013-09-23 2015-03-26 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
MD4794B1 (ro) 2013-09-27 2022-02-28 Merck Sharp & Dohme Corp Derivaţi de chinolizină substituiţi utili ca inhibitori de integrază HIV
WO2015089847A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Spirocyclic heterocycle compounds useful as hiv integrase inhibitors
NO2717902T3 (https=) 2014-06-20 2018-06-23
WO2016027879A1 (ja) 2014-08-22 2016-02-25 塩野義製薬株式会社 インテグラーゼ阻害活性を有する多環性ピリドン誘導体
KR20170045308A (ko) 2014-08-27 2017-04-26 비브 헬스케어 유케이 (넘버5) 리미티드 인간 면역결핍 바이러스 복제의 억제제로서 이미다조[1,2-a]피리딘 유도체
WO2016090545A1 (en) 2014-12-09 2016-06-16 Merck Sharp & Dohme Corp. Spirocyclic heterocycle compounds useful as hiv integrate inhibitors
EP3229804B1 (en) 2014-12-09 2020-05-06 Merck Sharp & Dohme Corp. Spirocyclic heterocycle compounds useful as hiv integrase inhibitors
TWI695003B (zh) 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
WO2016154527A1 (en) 2015-03-26 2016-09-29 Merck Sharp & Dohme Corp. Phosphate-substituted quinolizine derivatives useful as hiv integrase inhibitors
JP6402259B2 (ja) 2015-04-02 2018-10-10 ギリアード サイエンシーズ， インコーポレイテッド 多環式カルバモイルピリドン化合物およびそれらの薬学的使用
WO2016187788A1 (en) 2015-05-25 2016-12-01 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds useful for treating hiv infection
US10548910B2 (en) 2015-11-17 2020-02-04 Merck Sharp & Dohme Corp. Amido-substituted pyridotriazine derivatives useful as HIV integrase inhibitors
WO2017087256A1 (en) 2015-11-17 2017-05-26 Merck Sharp & Dohme Corp. Spirocyclic pyridotriazine derivatives useful as hiv integrase inhibitors
WO2017106071A1 (en) 2015-12-15 2017-06-22 Merck Sharp & Dohme Corp. Spirocyclic quinolizine derivatives useful as hiv integrase inhibitors
WO2017113288A1 (en) 2015-12-31 2017-07-06 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
EP4299133A3 (en) 2016-06-23 2024-03-13 VIIV Healthcare Company Compositions and methods for the delivery of therapeutics
JOP20190130A1 (ar) 2016-12-02 2019-06-02 Merck Sharp & Dohme مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv)
US10934312B2 (en) 2016-12-02 2021-03-02 Merck Sharp & Dohme Corp. Tricyclic heterocycle compounds useful as HIV integrase inhibitors
WO2018109786A1 (en) 2016-12-16 2018-06-21 Cipla Limited Novel polymoprphs and salts of polycyclic carbamoyl pyridone derivatives
WO2018140368A1 (en) 2017-01-26 2018-08-02 Merck Sharp & Dohme Corp. Substituted quinolizine derivatives useful as hiv integrase inhibitors
MX2020003242A (es) 2017-09-22 2020-09-18 Jubilant Epipad LLC Compuestos heterociclicos como inhibidores de pad.
EP3752042B1 (en) 2018-02-13 2024-07-10 Cool Vapor Solutions Compositions for humidification and cooling of gas streams
CN112088005A (zh) 2018-04-27 2020-12-15 默沙东公司 可用作hiv整合酶抑制剂的三环杂环化合物
CN110526930B (zh) 2018-05-23 2022-06-03 莫云芬 抗hiv病毒的含硫多环-羟基吡啶酮甲酰胺类似物及其应用
CN112204029B (zh) 2018-05-31 2024-03-01 豪夫迈·罗氏有限公司 治疗性化合物
AU2019277547B2 (en) 2018-05-31 2024-10-10 Shionogi & Co., Ltd. Polycyclic pyridone derivative
WO2019244066A2 (en) 2018-06-19 2019-12-26 VIIV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
WO2020003093A1 (en) 2018-06-25 2020-01-02 VIIV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
EP3815689A4 (en) 2018-06-27 2022-04-20 National University Corporation Hokkaido University ARENAVIRUS GROWTH INHIBITOR WITH POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE
ES2970251T3 (es) 2018-10-22 2024-05-27 Univ Nebraska Profármacos antivirales y nanoformulaciones de los mismos
WO2020112931A1 (en) 2018-11-29 2020-06-04 Board Of Regents Of The University Of Nebraska Antiviral prodrugs and nanoformulations thereof
WO2020221294A1 (zh) 2019-04-30 2020-11-05 上海拓界生物医药科技有限公司 桥环-3,4-二氢-吡啶并[1,2-a]吡嗪-1,8-二酮化合物及其药物用途
RU2717101C1 (ru) 2019-06-03 2020-03-18 Андрей Александрович Иващенко Анелированные 9-гидрокси-1,8-диоксо-1,3,4,8-тетрагидро-2Н-пиридо[1,2-a]пиразин-7-карбоксамиды - ингибиторы интегразы ВИЧ, способы их получения и применения
WO2021093846A1 (zh) 2019-11-13 2021-05-20 上海拓界生物医药科技有限公司 新型四环杂环化合物及其药物用途
TWI902729B (zh) 2019-11-28 2025-11-01 日商鹽野義製藥股份有限公司 以組合整合酶阻礙劑及抗ｈｉｖ藥為特徵之ｈｉｖ感染症的預防及治療用醫藥
US12577241B2 (en) 2019-11-28 2026-03-17 Shionogi & Co., Ltd. Polycyclic pyridopyrazine derivative
IL295677B1 (en) 2020-02-24 2026-04-01 Gilead Sciences Inc Tetracyclic compounds for the treatment of HIV infection
CA3192145A1 (en) 2020-09-30 2022-04-07 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
TW202227445A (zh) 2020-10-30 2022-07-16 大陸商上海拓界生物醫藥科技有限公司 抑制基因缺陷的ｈｉｖ病毒的用途
FI4196479T3 (fi) 2021-01-19 2024-01-17 Gilead Sciences Inc Substituoituja pyridotriatsiiniyhdisteitä ja niiden käyttöjä
EP4294813B1 (en) 2021-02-16 2025-09-10 Merck Sharp & Dohme LLC Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
TWI856796B (zh) 2022-04-06 2024-09-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019160783A1 (en) 2018-02-15 2019-08-22 Merck Sharp & Dohme Corp. Tricyclic heterocycle compounds useful as hiv integrase inhibitors
WO2019230858A1 (ja) 2018-05-31 2019-12-05 塩野義製薬株式会社 多環性カルバモイルピリドン誘導体
WO2019236396A1 (en) 2018-06-05 2019-12-12 Merck Sharp & Dohme Corp. Tricyclic heterocycle compounds useful as hiv integrase inhibitors
WO2020075080A1 (en) 2018-10-10 2020-04-16 Janssen Biopharma, Inc. Macrocyclic flu endonuclease inhibitors
WO2020197991A1 (en) 2019-03-22 2020-10-01 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
WO2021007506A1 (en) 2019-07-11 2021-01-14 Nanjing Zhengxiang Pharmaceuticals Co., Ltd. Compounds useful to treat influenza virus infections

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024173998A (ja) * 2021-01-19 2024-12-13 ギリアード サイエンシーズ， インコーポレイテッド 置換ピリドトリアジン化合物及びその使用
JP7759459B2 (ja) 2021-01-19 2025-10-23 ギリアード サイエンシーズ， インコーポレイテッド 置換ピリドトリアジン化合物及びその使用

Also Published As

Publication number Publication date
TWI824384B (zh) 2023-12-01
US11613546B2 (en) 2023-03-28
KR20230134529A (ko) 2023-09-21
US11897892B2 (en) 2024-02-13
US20230257389A1 (en) 2023-08-17
JP2024503116A (ja) 2024-01-24
PL4196479T3 (pl) 2024-03-18
SA523441639B1 (ar) 2024-07-31
LT4196479T (lt) 2023-12-11
JP2025087755A (ja) 2025-06-10
SI4196479T1 (sl) 2024-01-31
AU2022210247B2 (en) 2024-07-18
ZA202306360B (en) 2024-04-24
TW202237128A (zh) 2022-10-01
TW202408533A (zh) 2024-03-01
DK4196479T3 (da) 2024-01-22
CA3202957A1 (en) 2022-07-28
US20240300966A1 (en) 2024-09-12
HUE064467T2 (hu) 2024-03-28
CO2023009518A2 (es) 2023-07-21
EP4321217A3 (en) 2024-04-10
CL2023002074A1 (es) 2024-01-12
DK4196479T5 (da) 2025-01-02
EP4196479A1 (en) 2023-06-21
US20220267343A1 (en) 2022-08-25
JP7759459B2 (ja) 2025-10-23
HRP20231654T2 (hr) 2025-01-03
AU2024223997A1 (en) 2024-10-24
CL2024001793A1 (es) 2024-11-15
MX2023008137A (es) 2023-07-21
EP4321217A2 (en) 2024-02-14
US20250188089A1 (en) 2025-06-12
EP4196479B1 (en) 2023-11-01
PT4196479T (pt) 2024-01-03
DOP2023000139A (es) 2023-08-15
CR20230315A (es) 2023-09-01
WO2022159387A1 (en) 2022-07-28
ES2968058T3 (es) 2024-05-07
PE20231297A1 (es) 2023-08-22
US12187734B2 (en) 2025-01-07
IL304222A (en) 2023-09-01
FI4196479T3 (fi) 2024-01-17
AU2022210247A9 (en) 2024-05-09
PE20242099A1 (es) 2024-10-28
EP4196479B9 (en) 2024-10-16
AU2022210247C1 (en) 2024-10-31
HRP20231654T1 (hr) 2024-03-15
AU2022210247A1 (en) 2023-08-17
JP2024173998A (ja) 2024-12-13

Similar Documents

Publication Publication Date Title
JP7591155B2 (ja) 置換ピリドトリアジン化合物及びその使用
KR102934440B1 (ko) 가교된 트리사이클릭 카르바모일피리돈 화합물 및 이의 용도
US12122776B2 (en) Tetracyclic compounds and uses thereof
CN116745292A (zh) 经取代的吡啶并三嗪化合物及其用途
HK40104840A (en) Substituted pyridotriazine compounds and uses thereof
HK40094146A (en) Substituted pyridotriazine compounds and uses thereof
HK40094146B (en) Substituted pyridotriazine compounds and uses thereof
EA051450B1 (ru) Замещенные соединения пиридотриазина и их применение
KR20250093585A (ko) Hiv 감염을 치료하기 위한 사환식 화합물
EA051994B1 (ru) Тетрациклические соединения для лечения вич-инфекции

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230727

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230727

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240624

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240624

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240924

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241105

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241115

R150 Certificate of patent or registration of utility model

Ref document number: 7591155

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150